Repligen Corporation

Company Profile

Repligen Corporation had its IPO on 1990-03-26 under the ticker symbol RGEN.

The company operates in the Healthcare sector and Medical Instruments & Supplies industry. Repligen Corporation has a staff strength of 2,025 employees.

Stock update

Shares of Repligen Corporation opened at $162.78 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $157.47 - $162.78, and closed at $157.88.

This is a -3.18% slip from the previous day's closing price.

A total volume of 549,699 shares were traded at the close of the day’s session.

In the last one week, shares of Repligen Corporation have slipped by -10.16%.

Repligen Corporation's Key Ratios

Repligen Corporation has a market cap of $9.09 billion, indicating a price to book ratio of 5.3682 and a price to sales ratio of 11.6586.

In the last 12-months Repligen Corporation’s revenue was $729.33 million with a gross profit of $455.71 million and an EBITDA of $196.74 million. The EBITDA ratio measures Repligen Corporation's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Repligen Corporation’s operating margin was 18.98% while its return on assets stood at 3.46% with a return of equity of 7.31%.

In Q2, Repligen Corporation’s quarterly earnings growth was a negative -60.2% while revenue growth was a negative 23.3%.

Repligen Corporation’s PE and PEG Ratio

Forward PE

56.4972

Trailing PE

70.2845

PEG

2.59

Its diluted EPS in the last 12-months stands at $2.32 per share while it has a forward price to earnings multiple of 56.4972 and a PEG multiple of 2.59. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Repligen Corporation’s profitability.

Repligen Corporation stock is trading at a EV to sales ratio of 12.1008 and a EV to EBITDA ratio of 38.2. Its price to sales ratio in the trailing 12-months stood at 11.6586.

Repligen Corporation stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$2.55 billion

Total Liabilities

$373.58 million

Operating Cash Flow

$0

Capital Expenditure

$9.39 million

Dividend Payout Ratio

0%

Repligen Corporation ended 2024 with $2.55 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $2.55 billion while shareholder equity stood at $446.17 million.

Repligen Corporation ended 2024 with $0 in deferred long-term liabilities, $373.58 million in other current liabilities, 557000.00 in common stock, $446.17 million in retained earnings and $870.69 million in goodwill. Its cash balance stood at $603.66 million and cash and short-term investments were $603.66 million. The company’s total short-term debt was $2,889,000 while long-term debt stood at $0.

Repligen Corporation’s total current assets stands at $998.58 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $120.30 million compared to accounts payable of $23.79 million and inventory worth $240.87 million.

In 2024, Repligen Corporation's operating cash flow was $0 while its capital expenditure stood at $9.39 million.

Comparatively, Repligen Corporation paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$157.88

52-Week High

$235.06

52-Week Low

$134.64

Analyst Target Price

$200.73

Repligen Corporation stock is currently trading at $157.88 per share. It touched a 52-week high of $235.06 and a 52-week low of $235.06. Analysts tracking the stock have a 12-month average target price of $200.73.

Its 50-day moving average was $163.83 and 200-day moving average was $168.24 The short ratio stood at 8.61 indicating a short percent outstanding of 0%.

Around 675.7% of the company’s stock are held by insiders while 9869.5% are held by institutions.